Role of immunohistochemical markers in subtyping endometrial cancers

• Research type

  Research Study

• Full title

  Role of ER, P53 and Ki-67 immunohistochemical markers in subtyping of endometrial adenocarcinoma

• IRAS ID

  138874

• Contact name

  Michael Scott

• Contact email

  michael.scott@uhsm.nhs.uk

• Sponsor organisation

  University Hospital of South Manchester NHS Foundation Trust

• Research summary

  The proposed research project will investigate whether using immunohistochemical (IHC) staining alongside the routine haematoxylin and eosin (H&E) stained tissue section will allow easier diagnosis of some cases where identifying the sub type of endometrial carcinoma is difficult with just the H&E section alone. This may help to ensure that the correct diagnosis is made and reduce any variation between different pathologists in diagnosis of difficult cases and make sure the correct clinical management is provided for the patient.

  The main aims of the proposed research will be to assess including the use of statistical analysis if each subtype of endometrial adenocarcinoma has the characteristic immunohistochemical staining profile which is expected and suggested in the literature.
  This will identify if these immunohistochemical markers may be useful for diagnosing a specific sub type of endometrial carcinoma such as endometrioid, clear cell or serous carcinomas. The proposed research project will be to carry out immunohistochemical staining using p53, ki-67, and oestrogen receptor (ER) antibodies on 60 anonymised consecutive cases of endometrial curettage specimens. All cases will be subtyped according to the routine Haematoxylin and Eosin (H&E) stained tissue section. And then the immunohistochemical staining will be carried out on p53, ER and ki-67. These results will be analysed and compared to see if they agree with the expected immunoprofile staining of these antibodies suggested in the literature for each subtype. The results are expected to show that endometrioid carcinomas will be positive for ER, negative for p53 and have low ki-67 proliferate index. It is expected that serous carcinomas will be positive for p53, have high ki-67 proliferate index and be negative for ER.

• REC name

  East Midlands - Derby Research Ethics Committee

• REC reference

  13/EM/0380

• Date of REC Opinion

  4 Oct 2013

• REC opinion

  Favourable Opinion